{"id":"apatinib-capecitabine-oxaliplatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL414804","moleculeType":"Small molecule","molecularWeight":"395.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Apatinib is a tyrosine kinase inhibitor that blocks VEGFR-2, reducing tumor angiogenesis and vascular permeability. Capecitabine is a fluoropyrimidine prodrug that converts to 5-FU for DNA synthesis inhibition, while oxaliplatin is a platinum agent causing DNA cross-linking. The combination leverages anti-angiogenic and cytotoxic mechanisms for enhanced anticancer activity.","oneSentence":"This combination uses apatinib to inhibit vascular endothelial growth factor receptor (VEGFR) signaling while capecitabine and oxaliplatin provide chemotherapy to target cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:01.708Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer or gastroesophageal junction cancer (Phase 3 investigation)"},{"name":"Advanced solid tumors (investigational)"}]},"trialDetails":[{"nctId":"NCT03813784","phase":"PHASE3","title":"A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-03-07","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":885},{"nctId":"NCT06893887","phase":"NA","title":"Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Nanjing Tianyinshan Hospital","startDate":"2025-05-22","conditions":"Hepatocellular Carcinoma(HCC)","enrollment":300},{"nctId":"NCT06881017","phase":"PHASE2","title":"Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2025-05-01","conditions":"Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction","enrollment":140},{"nctId":"NCT03228043","phase":"NA","title":"Apatinib for Resectable Colorectal Cancer","status":"WITHDRAWN","sponsor":"Nanchong Central Hospital","startDate":"2020-03-01","conditions":"Apatinib, Outcome, Fatal, Colorectal Cancer","enrollment":""},{"nctId":"NCT04715633","phase":"PHASE2","title":"PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-12-01","conditions":"Colorectal Cancer, Microsatellite Instability High","enrollment":53},{"nctId":"NCT06238752","phase":"PHASE2","title":"First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC","status":"COMPLETED","sponsor":"Renmin Hospital of Wuhan University","startDate":"2021-03-01","conditions":"Advanced Gastric Adenocarcinoma","enrollment":33},{"nctId":"NCT03472365","phase":"PHASE2","title":"A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-04-02","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":67},{"nctId":"NCT04338438","phase":"PHASE2","title":"Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2015-05-01","conditions":"Gastric Cancer","enrollment":37},{"nctId":"NCT04202978","phase":"PHASE1, PHASE2","title":"Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer","status":"UNKNOWN","sponsor":"Zhongshan Hospital Xiamen University","startDate":"2020-03-01","conditions":"Hepatic Metastasis of Colorectal Cancer","enrollment":23},{"nctId":"NCT03986385","phase":"PHASE3","title":"Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction","status":"UNKNOWN","sponsor":"Hebei Medical University","startDate":"2019-06-01","conditions":"Gastroesophageal Junction Adenocarcinoma","enrollment":180},{"nctId":"NCT03349866","phase":"PHASE2","title":"A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction","status":"UNKNOWN","sponsor":"Hebei Medical University","startDate":"2017-11-30","conditions":"Gastroesophageal Junction Adenocarcinoma","enrollment":48},{"nctId":"NCT03229096","phase":"PHASE2","title":"Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2017-02-01","conditions":"Chemotherapy Effect, Chemotherapeutic Toxicity, Gastric Cancer","enrollment":35},{"nctId":"NCT03598348","phase":"PHASE3","title":"Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2018-01-16","conditions":"Gastric Cancer","enrollment":288},{"nctId":"NCT03599778","phase":"PHASE1, PHASE2","title":"XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma","status":"UNKNOWN","sponsor":"Anhui Provincial Hospital","startDate":"2018-09-01","conditions":"Gastric Carcinoma","enrollment":52},{"nctId":"NCT03412994","phase":"PHASE2","title":"Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Liqiang Zhong","startDate":"2018-02-28","conditions":"Colorectal Neoplasms","enrollment":60},{"nctId":"NCT03355612","phase":"PHASE3","title":"XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2017-12-20","conditions":"Gastric Carcinoma","enrollment":456},{"nctId":"NCT02510469","phase":"PHASE2, PHASE3","title":"Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells","status":"UNKNOWN","sponsor":"Hebei Medical University","startDate":"2015-07","conditions":"Gastric Cancer","enrollment":48},{"nctId":"NCT02829385","phase":"PHASE2","title":"Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients","status":"UNKNOWN","sponsor":"Shoucheng Ma","startDate":"2016-06","conditions":"Colorectal Neoplasms","enrollment":53},{"nctId":"NCT02776527","phase":"PHASE4","title":"A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2016-04","conditions":"Gastric Cancer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Apatinib Capecitabine Oxaliplatin","genericName":"Apatinib Capecitabine Oxaliplatin","companyName":"Hebei Medical University","companyId":"hebei-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses apatinib to inhibit vascular endothelial growth factor receptor (VEGFR) signaling while capecitabine and oxaliplatin provide chemotherapy to target cancer cells. Used for Gastric cancer or gastroesophageal junction cancer (Phase 3 investigation), Advanced solid tumors (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}